Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

The clinical study was conducted by Daewoong's US partner Evolus on 150 patients

Daewoong Pharma's Nabota (US brand name: Jeuveau)
Daewoong Pharma's Nabota (US brand name: Jeuveau)
Jae-Young Han 1
2023-02-03 16:09:46 jyhan@hankyung.com
Bio & Pharma

Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wrinkles showed a six-month long-lasting effect as a result of an interim analysis of a phase 2 clinical trial.

Evolus, Daewoong Pharma's US partner, conducted the latest clinical trial on 150 patients under the age of 65 with moderate to severe frown lines.

A Daewoong Pharma official explained that long-lasting effects and safety were confirmed as a result of administering high-dose Jeuveau, which is about twice the usual dose of Jeuveau, and observing the effect of improving wrinkles between the eyebrows for six months.

"We plan to undertake marketing in large-scale botulinum toxin markets such as the US, Europe, and Canada. We will prove the effectiveness and safety of Nabota and expand our global market share through consistent clinical studies," said Park Seong-soo, vice president of Daewoong Pharmaceutical.

The results of this study were recently announced at the 2023 International Master Course on Aging Science (IMCAS) held in Paris, France.

Write to Jae-Young Han at jyhan@hankyung.com
#Daewoong Pharmaceutical #botulinum toxin #Nabota #Jeuveau #Evolus #korea daewoong nabota #daewoong jeuveau botulinum toxin

S.Korea's Daewoong Pharmaceutical to export tech to British company

S.Korea's Daewoong Pharmaceutical to export tech to British company

Daewoong Pharmaceutical's headquarters building South Korea's Daewoong Pharmaceutical has licensed a new drug candidate for idiopathic pulmonary fibrosis (IPF) to CS Pharmaceuticals (CSP) of the UK.Daewoong Pharmaceutical on Tuesday said it transferred to CSP the rights to develop and market Be

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Jan. 13.The item that received approval this time is Nuceiva 100 units whose application to the Australian authorities had been made by Nabota's cos

Daewoong accelerates investment in CDMO business

Daewoong accelerates investment in CDMO business

Daewoong Bio Laboratory Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development and manufacturing (CDMO) business.In its stock exchange filing on Monday, Daewoong revealed that its subsidiary Daewoong Bio

Daewoong, Onchorus to undertake research on mRNA anticancer drugs

Daewoong, Onchorus to undertake research on mRNA anticancer drugs

Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture Onchorus for messenger ribonucleic acid (mRNA) drugs.According to Daewoong, the Andover (Massachusetts)-based company possesses self-amplifying R
(* comment hide *}